![]() |
JOURNAL TOOLS |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |

YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW UPDATES ON MATERNAL FETAL MEDICINE
Minerva Ginecologica 2019 April;71(2):97-112
DOI: 10.23736/S0026-4784.18.04334-4
Copyright © 2018 EDIZIONI MINERVA MEDICA
language: English
Fetal anemia
Pedro S. ARGOTI ✉, Giancarlo MARI
Department of Obstetrics and Gynecology, Health Sciences Center, University of Tennessee, Memphis, TN, USA
The diagnosis and management of fetal anemia has been at the forefront of advances in the fields of fetal physiology, immunology, fetal imaging, and fetal therapy among others. Alloimmunization and parvovirus infection are the leading cause of fetal anemia in the United States. The middle cerebral artery peak systolic velocity (MCA-PSV) diagnoses fetal anemia. Its discovery is considered one of the most important achievements in fetal medicine. Accumulation of experience in recent years as well as refinement of surgical techniques have led to safer invasive procedures. It is expected that long term follow-up of affected pregnancies, continues to reflect all these improvements in care. It is also expected that treatment of other less common causes of fetal anemia becomes more frequently reported and that the management principles of fetal anemia are successfully applied to other fetal pathologies.
KEY WORDS: Anemia - Middle cerebral artery - Fetal erythroblastosis - Parvovirus - Intrauterine blood transfusion